COPD stands for complex obstructive pulmonary disease

European Respiratory Review

Volumn 27, Issue 148, 2018, Pages

  Houben Wilke, Sarah ^a   Augustin, Ingrid M ^b   Vercoulen, Jan H ^c   van Ranst, Dirk ^d   de Vaate, Eline Bij ^e   Wempe, Johan B ^f   Spruit, Martijn A ^b,g   Wouters, Emiel F M ^b,g   Franssen, Frits M E ^b,g  

^a Dutch Lung Centers   (Netherlands)

^b CIRO+   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Revant Pulmonary Rehabilitation Center 'schoondonck'   (Netherlands)

^e Merem Treatment Centers   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AIRWAY OBSTRUCTION; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION SUPPORT SYSTEM; COUGHING; DAILY LIFE ACTIVITY; DIASTOLIC BLOOD PRESSURE; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; GENETIC VARIATION; HUMAN; PATIENT ASSESSMENT; PATIENT-REPORTED OUTCOME; PEAK EXPIRATORY FLOW; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; PULMONARY REHABILITATION; PULSE RATE; REVIEW; SLEEP DISORDER; SMOKING; SOCIAL NETWORK; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; CLINICAL DECISION MAKING; COST OF ILLNESS; EMOTION; HEALTH STATUS; LUNG; MENTAL HEALTH; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR;

CLINICAL DECISION-MAKING; COMBINED MODALITY THERAPY; COST OF ILLNESS; EMOTIONS; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LUNG; MENTAL HEALTH; PATIENT SELECTION; PATIENT-CENTERED CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR;

EID: 85048339912     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0027-2018     Document Type: Review

References (94)

1. Agusti A, Calverley PM, Celli B, et al Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
2. Duffy S, Weir M, Criner Gj.The complex challenge of chronic obstructive pulmonary disease. Lancet Respir Med 2015; 3: 917-919.
3. Spruit MA, Augustin IM, Vanfleteren LE, et al Differential response to pulmonary rehabilitation in COPD: multidimensional profiling. Eur Respir J 2015; 46: 1625-1635.
4. Vanfleteren LE, Spruit MA, Groenen M, et al Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
5. Divo MJ, Casanova C, Marin JM, et al COPD comorbidities network. Eur Respir J 2015; 46: 640-650.
6. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? Ann Am Thorac Soc 2013; 10: Suppl, S125-S130.
7. Wouters EF, Wouters BB, Augustin IM, et al. Personalized medicine and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2017; 23: 241-246.
8. Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008; 372: 1088-1099.
9. Vogelmeier CF, Criner GJ, Martinez FJ, et al Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195: 557-582.
10. Dijk WD, Bemt L, Haak-Rongen S, et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res 2011; 12: 151.
11. Slok AH, In’t Veen JC, Chavannes NH, et al Development of the assessment of burden of COPD tool: an integrated tool to measure the burden of COPD. NPJ Prim Care Respir Med 2014; 24: 14021.
12. Agusti A. The path to personalised medicine in COPD. Thorax 2014; 69: 857-864.
13. Rodriguez-Roisin R, Rabe KF, Vestbo J, et al Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. Eur Respir J 2017; 50: 1700671.
14. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
15. Peters JB, Daudey L, Heijdra YF, et al Development of a battery of instruments for detailed measurement of health status in patients with COPD in routine care: the Nijmegen Clinical Screening Instrument. Qual Life Res 2009; 18: 901-912.
16. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
17. Castaldi PJ, Benet M, Petersen H, et al Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. Thorax 2017; 72: 998-1006.
18. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68: 687-690.
19. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
20. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.
21. Augustin IM, Wouters EFM. Process of pulmonary rehabilitation and program organization. J Card Pulm Rehabil 2017; 1: 109.
22. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
23. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
24. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017; 5: 619-626.
25. Smid DE, Franssen FME, Gonik M, et al. Redefining cut-points for high symptom burden of the global initiative for chronic obstructive lung disease classification in 18,577 patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc 2017; 18: 1097.
26. Vercoulen JH. A simple method to enable patient-tailored treatment and to motivate the patient to change behaviour. Chron Respir Dis 2012; 9: 259-268.
27. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
28. Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int 2014; 2014: 4201-34.
29. Agusti A, Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur Respir J 2011; 38: 749-751.
30. Blue bloater: pink puffer. Br Med J 1968; 2: 677.
31. Cosio BG, Soriano JB, Lopez-Campos JL, et al. Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PloS one 2016; 11: e0160770.
32. Mirza S, Benzo R. Chronic obstructive pulmonary disease phenotypes: implications for care. Mayo Clinic 2017; 92: 1104-1112.
33. Peters JB, Boer LM, Molema J, et al. Integral health status-based cluster analysis in moderate-severe COPD patients identifies three clinical phenotypes: relevant for treatment as usual and pulmonary rehabilitation. Int J Behav Med 2017; 24: 571-583.
34. Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015; 385: 1789-1798.
35. Wardlaw AJ, Silverman M, Siva R, et al. Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005; 35: 1254-1262.
36. Pinto LM, Alghamdi M, Benedetti A, et al. Derivation and validation of clinical phenotypes for COPD: a systematic review. Respir Res 2015; 16: 50.
37. Esteban C, Arostegui I, Aburto M, et al. Chronic obstructive pulmonary disease subtypes. transitions over time. PloS one 2016; 11: e0161710.
38. Agusti A, Gea J, Faner R. Biomarkers, the control panel and personalized COPD medicine. Respirology 2016; 21: 24-33.
39. Agusti A, Anto JM, Auffray C, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med 2015; 191: 391-401.
40. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-2234.
41. Lange P, Halpin DM, O’Donnell DE, et al. Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1). Int J Chron obstruct Pulm Dis 2016; 11: 3-12.
42. Houben-Wilke S, Franssen FM, Kok I, et al. Assessment of Burden of COPD (ABC) tool: perception versus evidence. Eur Respir J 2017; 49: 1602382.
43. Willson A. The problem with eliminating “low-value care”. BMJ Qual Saf 2015; 24: 611-614.
44. Postma DS, Anzueto AR, Jenkins C, et al. Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristics. Respir Med 2013; 107: 1939-1947.
45. Rogowski W, Payne K, Schnell-Inderst P, et al. Concepts of “personalization” in personalized medicine: implications for economic evaluation. PharmacoEconomics 2015; 33: 49-59.
46. Annegarn J, Meijer K, Passos VL, et al. Problematic activities of daily life are weakly associated with clinical characteristics in COPD. J Am Med Dir Assoc 2012; 13: 284-290.
47. Vaes AW, Wouters EF, Franssen FM, et al. Task-related oxygen uptake during domestic activities of daily life in patients with COPD and healthy elderly subjects. Chest 2011; 140: 970-979.
48. Lahousse L, Ziere G, Verlinden VJ, et al Risk of frailty in elderly with COPD: a population-based study. J Gerontol A Biol Sci Med Sci 2016; 71: 689-695.
49. Crisan AF, Oancea C, Timar B, et al. Balance impairment in patients with COPD. PloS one 2015; 10: e0120573.
50. Annegarn J, Spruit MA, Savelberg HH, et al. Differences in walking pattern during 6-min walk test between patients with COPD and healthy subjects. PloS one 2012; 7: e37329.
51. Lahousse L, Verlinden VJ, van der Geest JN, et al Gait patterns in COPD: the Rotterdam Study. Eur Respir J 2015; 46: 88-95.
52. Dedding C, Cardol M, Eyssen IC, et al Validity of the Canadian occupational performance measure: a client-centred outcome measurement. Clin Rehabil 2004; 18: 660-667.
53. Kosteli MC, Heneghan NR, Roskell C, et al. Barriers and enablers of physical activity engagement for patients with COPD in primary care. Int J Chron Obstruct Pulm Dis 2017; 12: 1019-1031.
54. Mesquita R, Nakken N, Janssen DJA, et al. Activity levels and exercise motivation in patients with COPD and their resident loved ones. Chest 2017; 151: 1028-1038.
55. Chen Z, Fan VS, Belza B, et al. Association between social support and self-care behaviors in adults with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2017; 14: 1419-1427.
56. Lee H, Yoon JY, Kim I, et al. The effects of personal resources and coping strategies on depression and anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 2013; 42: 473-479.
57. Nakken N, Janssen DJ, van den Bogaart EH, et al Informal caregivers of patients with COPD: home sweet home? Eur Respir Rev 2015; 24: 498-504.
58. Gabriel R, Figueiredo D, Jacome C, et al. Day-to-day living with severe chronic obstructive pulmonary disease: towards a family-based approach to the illness impacts. Psychol Health 2014; 29: 967-983.
59. Nakken N, Janssen DJ, van den Bogaart EH, et al. Patient versus proxy-reported problematic activities of daily life in patients with COPD. Respirology 2017; 22: 307-314.
60. Nakken N, Spruit MA, van den Bogaart EH, et al. Health status and morbidities in resident relatives of patients with COPD. J Am Med Dir Assoc 2016; 17: 276 e271-278.
61. Aasbo G, Rugkasa J, Solbraekke KN, et al. Negotiating the care-giving role: family members’ experience during critical exacerbation of COPD in Norway. Health Soc Care Community 2017; 25: 612-620.
62. Fotokian Z, Mohammadi Shahboulaghi F, Fallahi-Khoshknab M, et al. The empowerment of elderly patients with chronic obstructive pulmonary disease: managing life with the disease. PloS one 2017; 12: e0174028.
63. Greenhalgh T. Patient and public involvement in chronic illness: beyond the expert patient. BMJ 2009; 338: b49.
64. US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
65. Ekstrom M, Sundh J, Larsson K. Patient reported outcome measures in chronic obstructive pulmonary disease: which to use? Expert Rev Respir Med 2016; 10: 351-362.
66. Vanfleteren L, Spruit MA, Wouters EFM, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med 2016; 4: 911-924.
67. Stoilkova A, Wouters EF, Spruit MA, et al. The relationship between coping styles and clinical outcomes in patients with COPD entering pulmonary rehabilitation. COPD 2013; 10: 316-323.
68. Meis JJ, Bosma CB, Spruit MA, et al. A qualitative assessment of COPD patients’ experiences of pulmonary rehabilitation and guidance by healthcare professionals. Respir Med 2014; 108: 500-510.
69. Brien SB, Lewith GT, Thomas M. Patient coping strategies in COPD across disease severity and quality of life: a qualitative study. NPJ Prim Care Respir Med 2016; 26: 16051.
70. Benzo RP, Kirsch JL, Dulohery MM, et al. Emotional intelligence: a novel outcome associated with wellbeing and self-management in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2016; 13: 10-16.
71. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887.
72. Wilke S, Jones PW, Mullerova H, et al One-year change in health status and subsequent outcomes in COPD. Thorax 2015; 70: 420-425.
73. Paddison JS, Effing TW, Quinn S, et al Fatigue in COPD: association with functional status and hospitalisations. Eur Respir J 2013; 41: 565-570.
74. Peters JB, Heijdra YF, Daudey L, et al. Course of normal and abnormal fatigue in patients with chronic obstructive pulmonary disease, and its relationship with domains of health status. Patient Educ Couns 2011; 85: 281-285.
75. Todt K, Skargren E, Kentson M, et al. Experience of fatigue, and its relationship to physical capacity and disease severity in men and women with COPD. Int J Chron Obstruct Pulm Dis 2014; 9: 17-25.
76. Antoniu SA, Ungureanu D. Measuring fatigue as a symptom in COPD: from descriptors and questionnaires to the importance of the problem. Chron Respir Dis 2015; 12: 179-188.
77. Al-Shair K, Kolsum U, Singh D, et al. The Effect of fatigue and fatigue intensity on exercise tolerance in moderate COPD. Lung 2016; 194: 889-895.
78. Kentson M, Todt K, Skargren E, et al. Factors associated with experience of fatigue, and functional limitations due to fatigue in patients with stable COPD. Ther Adv Respir Dis 2016; 10: 410-424.
79. Kaljouw M, van Vliet K. Naar nieuwe zorg en zorgberoepen: de contouren [Towards new care and care professions: the contours]. www.rijksoverheid.nl/…/naar-nieuwe-zorg-en-zorgberoepen-de-contouren.pdf Date last updated: April 10, 2015; date last accessed: September 26, 2015.
80. Federatie Medisch Specialisten. Visiedocument: Medisch Specialist 2025: ambitie, vertrouwen, samenwerken. 2017. www.demedischspecialist.nl/sites/default/files/Visiedocument%20Medisch%20Specialist%202025-DEF.pdf Date last accessed: March 29, 2017.
81. Zhang L, Tong H, Demirel HO, et al. A practical model of value co-creation in healthcare service. Procedia Manufacturing 2015; 3: 200-2007.
82. Steiner MC, Roberts CM. Pulmonary rehabilitation: the next steps. Lancet Respir Med 2016; 4: 172-173.
83. Hodgkin JE, Farrell MJ, Gibson SR, et al. American Thoracic Society. Medical Section of the American Lung Association. Pulmonary rehabilitation. Am Rev Respir Dis 1981; 124: 663-666.
84. Fishman AP. Pulmonary rehabilitation research. Am J Respir Crit Care Med 1994; 149: 825-833.
85. Houben-Wilke S, Augustin IM, Wouters BB, et al. The patient with a complex chronic respiratory disease: a specialist of his own life? Expert Rev Respir Med 2017; 11: 919-924.
86. Holland AE, Spruit MA, Troosters T, et al An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428-1446.
87. Huber M, Knottnerus JA, Green L, et al How should we define health? BMJ 2011; 343: d4163.
88. Huber M, van Vliet M, Giezenberg M, et al Towards a “patient-centred” operationalisation of the new dynamic concept of health: a mixed methods study. BMJ Open 2016; 6: e010091.
89. Elwyn G, Laitner S, Coulter A, et al Implementing shared decision making in the NHS. BMJ 2010; 341: c5146.
90. Harb N, Foster JM, Dobler CC. Patient-perceived treatment burden of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulm Dis 2017; 12: 1641-1652.
91. Wilson T, Holt T, Greenhalgh T. Complexity science: complexity and clinical care. BMJ 2001; 323: 685-688.
92. Alison JA, McKeough ZJ, Johnston K, et al Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology 2017; 22: 800-819.
93. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in adults. https://www.nice.org.uk/guidance/qs10/resources/chronic-obstructive-pulmonary-disease-in-adults-pdf-2098478592709 Date last updated: February 2016; date last accessed: November 2017.
94. Wouters EF, Augustin IM. COPD health-care delivery: a holistic and dynamic approach is needed. Lancet Respir Med 2016; 4: e30-e31.